Co-Producer
|
|
| SEPTEMBER
29, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
Kate Torchilin, Ph.D., M.B.A., CEO and
President, Mirai Bio |
In
this CEO Q&A, Torchilin discusses the
delivery bottleneck that inspired Mirai's
founding, what differentiates its
integrated LNP platform, the milestone
that took a partner program from concept
to IND-enabling studies in under ten
months, and leading within the Flagship
Pioneering ecosystem. More
|
|
|
|
|
Join
us September 30 – October 1 for
LSPA’s largest partnering event of
the year. Connect with the life
sciences ecosystem throughout the
Commonwealth and beyond, get the
latest information through timely
panel discussions and learn about
the newest innovations shaping the
industry.
|
|
Learn More
→ |
|
|
- CSL and AWS: Collaborate to Advance
Biopharmaceutical R&D More
- Medicus Pharma: Submits Optimized Teverelix
Registrational Protocol to FDA to Create
Partner Ready Program in Advanced Prostate
Cancer More
- Novo Nordisk: Ozempic (Semaglutide) 2 mg
Associated With Lower Risk of Major Adverse
Cardiovascular Events (Death, Heart Attack,
and Stroke) in Adults With Type 2 Diabetes
Compared to Switching to Mounjaro
(Tirzepatide), in Real-World Analysis at EASD
More
- Teleflex: Latest Peer-Reviewed Study
Demonstrates a Significant Reduction in CLABSI
Risk With Arrowg+ard Technology More
|
|
 |
|
Investment Banking Advisory to the
Life Science Industry |
|
Learn More
→ |
|
|
- AstraZeneca: Makes $2 Billion Strategic
Equity Investment in Summit Therapeutics More
More
More*
- Cell Therapy Firm Grows Footprint With
85,000-square-foot Montgomery County
Acquisition More*
- IMUNON: Converts $1.2 Million of
Debt-to-Equity More
- Iovance Biotherapeutics: Raises Full Year
2026 Revenue Guidance to $410 to $420 Million
More
- More on Tolerance Continuing
Thymus-Focused Deals With $560M Pact for
Tanabe's Clinical-Stage IL-33 Drug More
- Reverse Mergers and SPACs – H1 2026 Review More
|
|
 |
| The
future of advanced therapies:
Explore challenges and
opportunities shaping patient
access, site-of-care expansion and
commercialization. |
| Access the
Report → |
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- As Retirement Nears, CHOP CEO Madeline Bell
Weighs In on Health Care’s Future More*
- Big4Bio CEO Weekly Q&A: Kate
Torchilin, Ph.D., M.B.A., CEO and President,
Mirai Bio More
- Biotech & Pharma Updates | September 28,
2026 More
- Subscribe to LifeSci Startup for
Updates on US Startups More
- The Biotech Startups Podcast: How Teaching
High School Prepares You to Run a Company Podcast
|
|
 |
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- ICYMI:
Cencora: Elects Robert E. Sanchez to Its Board
of Directors More
- ICYMI:
Chutes & Ladders—Travere Chief Makes Way
for Former Amicus CEO More
- Minaris: Evolves Business Model With
Addition of Dedicated Viral Vectors Business
Unit More
- OPPORTUNITY: Vice President, Business
Development, Remote More
- OPPORTUNITY: Director of Compliance, Remote
More
- Slone Partners: Beyond the Org Chart
- Redefining Leadership Roles After an
Acquisition More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Philadelphia Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Philadelphia,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
